Rahul Khara, who serves as the Chief Legal Officer at Disc Medicine, Inc. (NASDAQ:IRON), executed a series of stock transactions totaling $187,500 in late June 2026. The sales involved 2,500 shares of the company's common stock, distributed across two dates: June 26 and June 29, 2026. Each share was sold at a price of $75.00.
These sales were preceded by the acquisition of an identical number of shares through the exercise of stock options. On the same dates, Mr. Khara acquired 2,500 shares of common stock by exercising options priced at $14.69 per share, resulting in a total acquisition cost of $36,725. The options utilized for this exercise were fully vested and immediately exercisable.
All reported transactions by Mr. Khara were carried out pursuant to a Rule 10b5-1 trading plan, which was adopted on March 19, 2026. Following these transactions, Mr. Khara directly holds 52,173 shares of Disc Medicine common stock.
The transactions occur as Disc Medicine shares trade at $73.09, giving the biotech company a market cap of $2.8 billion. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value estimate. Despite current unprofitability, the stock has delivered strong returns of 38% over the past year, though investors should note its high beta of 2.1 signals significant volatility. Analysts remain optimistic, setting price targets between $79 and $128.
In other recent news, Disc Medicine Inc. presented updated clinical trial data for two investigational treatments at the European Hematology Association Annual Meeting. The RALLY-MF trial involved 61 adult patients with myelofibrosis and anemia, with 50 patients included in the responder analysis. Additionally, the company completed a Type A meeting with the U.S. Food and Drug Administration regarding bitopertin in erythropoietic protoporphyria. The FDA agreed that the ongoing Phase 3 APOLLO study, if successful, could potentially support a traditional approval. Disc Medicine also launched an expanded access program for bitopertin, providing access to eligible patients in the U.S. prior to regulatory approval. Furthermore, Stifel reiterated a Buy rating on Disc Medicine following the presentation of Phase 2 RALLY-MF trial data, noting the drug’s efficacy. Lastly, Disc Medicine announced it would present data from its RALLY-MF Phase 2 trial at the American Society of Clinical Oncology Annual Meeting.